I can extract side effects

Unsurprisingly, Wei Kang received a call from Andre again.

"Dear Wei, it's like this. Last time I ordered a batch of ARC1 protein samples, they were unanimously approved by the Pfizer team of scientists. Everyone is very optimistic about this technology and wants to apply it in biopharmaceuticals. field."

"So on behalf of the company, I want to talk to you about patent licensing fees."

Andre didn't hide it, but directly explained the purpose of coming. He had already figured out Wei Kang's general temperament, and knew that the other party's personality was relatively straightforward. Only by treating him with sincerity can we continue to cooperate.

"No problem, our cooperation has always been very pleasant, and I will give you a discounted price as an old friend." Wei Kang replied with a smile.

Speaking of the preferential price, Andre had an idea and suddenly remembered something.

This Mr. Wei seems to have a rather unique hobby. He likes to collect used prescriptions. In the last anti-cancer drug negotiation, he also asked pharmaceutical companies to provide discarded prescriptions in order to be eligible for bidding.

From this point of view, you might as well choose what you like and see if you can negotiate a lower price.

Andre was a little embarrassed: "Dear Wei, recently the company has made a series of strategic adjustments to focus on the research and development of innovative drugs and vaccines. In the past six months, it has been doing a lot of mergers and acquisitions, and its cash flow is consuming a lot."

"Especially last month, it spent US$11.6 billion to acquire the pharmaceutical company Biohaven. Now the account is already stretched, and we can't spend much money. However, Pfizer has a big business, and there are many companies and pipelines under it. If you are interested, We can exchange some of the divested business."

"In short, we hope to minimize the payment of cash, and it is best to pay the patent license fee in other ways."

"Oh," Wei Kang suddenly became interested, and asked, "What strategic adjustments do you have? What businesses do you want to divest and sell?"

Andre immediately began to talk endlessly: "The company's current goal is to embrace digitalization. It recently announced a digital upgrade plan to shift more medical staff to online interaction, develop Internet channels, and strengthen digital development strategies. You three clearly understand this. Have been doing a great job and we have to learn from you."

"We will also focus on tumors, rare diseases, immunity and inflammation, vaccines and other fields, and have acquired four companies in these fields, obtained Lyme disease vaccines, blockbuster migraine drugs on the market, and respiratory antivirals Drugs, as well as multiple research pipelines such as immune and inflammatory diseases.”

"So in the future, part of the business will definitely be sold to withdraw funds to maintain a balance of payments."

"The businesses that have been spun off, including the consumer healthcare business and the generic drug business, have set up joint venture companies and only hold shares. This year, we will completely sell all the shares and withdraw from these two major businesses. If Sanqing is also interested , everything is easy to talk about."

Andre continued calmly: "In addition, all acquired companies will divest and sell bad assets, including failed R\u0026D projects, abandoned prescriptions, expired patents, delisted drugs, and money-losing ones. Business, wait."

"As far as I know, in addition to Pfizer, other multinational pharmaceutical companies are also adjusting their strategic layout and divesting non-performing assets to ease performance pressure."

"Sanofi has been hit hard recently and is preparing to sell its shares in its API company. Merck is also selling its women's health business, and GSK plans to spin off its consumer healthcare business. AstraZeneca has also sold a number of fields. blockbuster drug."

Andre has worked in the pharmaceutical industry for many years, knows the trends of major pharmaceutical companies well, and keeps telling the latest trends.

Weikang was fascinated by this, and was a little moved. Sanqing now has an annual revenue of 40 billion, which can be said to be a huge amount of money. Like other pharmaceutical companies, it can obtain new growth points through mergers and acquisitions.

Especially in recent years, the competition among pharmaceutical companies has become more and more fierce. Facing the pressure brought by events such as drug price cuts, centralized procurement, and patent expirations, many multinational pharmaceutical companies are selling their products at a high price. Overcoming difficulties and looking for new business breakthroughs.

Although Sanqing now has many blockbuster drugs and ace drugs, it is still lacking in the layout of the entire drug production line. This is also the disadvantage of the short rise time, which is not as rich as those pharmaceutical companies with hundreds of years of experience.

A giant like Pfizer has hundreds of drugs under development every year, and dozens of drugs have failed or been abolished. After so many years of accumulation, there are estimated to be tens of thousands of prescriptions in the warehouse.

Thinking about it, Wei Kang's heart became hot, but it's a pity that these prescriptions don't belong to him, and they can't be used as waste.

At this moment, the words 'failed research and development project', 'abandoned prescription', and 'strip sale' suddenly floated into my ears.

He was stunned for a moment, and then his eyes lit up, and his heart couldn't help beating rapidly.

Great, why didn't he think of that?

Abandoned prescriptions are not enough, so you can find someone else to buy them.

Usually when the performance of pharmaceutical companies is good, they may not be willing to sell them, but they have restructured their businesses and sold off their bad assets, so they are naturally willing to sell them at a low price in exchange for some cash.

Of course, it should not be too obvious, and it can be packaged and acquired together with some other cheap assets.

These multinational pharmaceutical companies are all pure-blooded capitalists, and they are absolutely willing to sell and squeeze out the last drop of oil and water.

After all, what Weikang needs is only a discarded prescription that has passed the first phase of clinical trials.

Of the slightly larger pharmaceutical companies, which warehouse does not have double-digit discarded prescriptions?

If they are all sold, they can be sold for millions of dollars. For many pharmaceutical companies, this is a windfall, and it is worthwhile to recover a little loss.

Especially for some pharmaceutical companies that are about to go bankrupt, this money is a life-saving straw, and it can last for a while, and maybe they can be brought back to life.

Wei Kang was very excited, but his face remained calm, he nodded and said in agreement: "Yes, after this adjustment, Pfizer must be able to rejuvenate and reach new heights in the field of innovative drugs."

"I am very interested in what you said. You also know that Sanqing's current foundation is still very shallow, and it needs to acquire some other businesses. Pfizer's target field does not overlap with Sanqing. space where we can collaborate with each other.”

Among the several areas that Pfizer focuses on, the tumor must cooperate with Sanqing’s anticancer drugs.

The list of rare diseases is too big, there are 3,000 kinds of diseases, no matter what, it is enough to pose a threat.

As for the vaccine business, anti-virus and immune inflammation, Sanqing has not entered these markets at all, and there is no competition.

Seeing that Wei Kang's response was much more enthusiastic, Andre immediately burst out laughing.

While he was in a happy mood, he also said something in his heart.

"Dear Wei, you are always so smart. The pharmaceutical market is huge, and even a small part of it can make huge profits. We can complement each other in many ways, and we can eat this cake together."

"In fact, I don't agree with behaviors like the Broad Institute's. Being too greedy will only kill the chicken and take the eggs, ruining the prospect of gene patents. I am more optimistic about the cooperation with Sanqing. You have stronger technology, but are more tolerant and have a longer-term perspective. .”

"With the ARC1 protein patent, Sanqing has become invincible in the field of gene editing. What you need are friends, the more the better, so that you can get a steady stream of profits. What do you think?"

Wei Kang greatly praised that Andre was far smarter than he imagined, and it was obvious that his position belonged to the open camp, not the conservative camp.

"This person can be recruited and used for me, but I don't know if there are many people like him in the West." He thought to himself.

The two sides talked very happily, and soon reached a preliminary agreement.

In a few days, Andre will bring a team over to formally sign the patent licensing contract.

At the same time, Wei Kang is also very interested in the non-performing assets that Pfizer wants to sell.

This divestiture sells all the non-performing assets of the acquired company, so it doesn't hurt at all to sell.

Pfizer only cares about the blockbuster drugs of those companies and their research and development capabilities in this field. As for other superfluous things, they don't care at all.

Wei Kang quickly negotiated a very cheap price.

Pfizer deserves to be a big player in mergers and acquisitions. It spends billions of dollars in the pharmaceutical industry every year. It is a super big money owner who keeps buying and buying. It has a lot of inventory. It has acquired no less than 10 companies in the past two years alone.

This time, I sold the non-performing assets of 8 acquired companies in one go, including but not limited to all abandoned prescriptions, delisted drugs, drugs with no development prospects, and several patents that did not sell well and were about to expire.

In order to fight for preferential patent licensing fees, Andre even persuaded the CEO to include some discarded prescriptions within Pfizer.

Of course, these are relatively old stocks, and they have been eating ashes on the shelves of the laboratory for at least five or six years, and the kind that don’t feel bad for free gifts.

Because it is a big sale, the price is very affordable, probably around 20 million US dollars.

Pfizer does not intend to pay cash, and all of it will be included in the first batch of patent licensing fees paid.

Wei Kang is equivalent to reducing or exempting some patent fees, and then in exchange for a lot of abandoned prescriptions and drugs with no future.

And Pfizer paid some ballast waste in exchange for a very favorable discount and a reduction in patent licensing fees.

It was all barter, and no cash was spent.

Both parties are very happy, and both feel that they have taken advantage of the sky.

After this incident, Weikang tasted the sweetness and couldn't help thinking of other multinational pharmaceutical companies.

As Andre said, Sanofi, AstraZeneca, Merck, Novartis, etc., these pharmaceutical companies are all slimming down and reorganizing, stripping off bad assets, and he can do the same, exchanging patent licensing fees for obsolete prescriptions.

The news of the deal between Pfizer and Sanqing quickly spread in the industry.

*****

The capital city of the cherry blossom country, Dajing.

In a high-rise building in the city center, the CEO of Eisai Pharmaceuticals, Okada Muruo, is sighing, worried about the company's plummeting performance.

Eisai Pharmaceuticals is one of the five major pharmaceutical giants in Sakura Country, with annual sales reaching US$6 billion, ranking among the top 50 pharmaceutical giants in the world.

This is a typical pharmaceutical company that relies on explosive products to make a fortune quickly. It once entered the top 20 in the world rankings, but with the passage of time, Eisai's position in the global pharmaceutical market has been greatly reduced.

Relying on two explosive products, donepezil and rabeprazole, the company has reached cooperation with Pfizer and Johnson \u0026 Johnson respectively. With the efforts of the two giants, it has obtained billions of dollars in huge revenue in just a few years.

However, innovative drugs have always been a high-risk gamble. If you want to achieve long-term success in the innovative drug industry, you must solve the problem of the patent cliff.

The patent cliff refers to the fact that after the patent expires, a large number of cheap generic drugs emerge and seize the market, causing the sales of the original research drug to plummet like falling off a cliff.

Eisai has been able to successfully create two explosive products, but this does not mean that its own research and development capabilities can be on par with multinational giants.

On the contrary, Eisai, which relied on Me-too's improved drug to successfully go overseas, has a huge gap in innovation ability with Western pharmaceutical giants.

When the company was prosperous at the beginning, it did not plan ahead and carried out a large number of mergers and acquisitions in a timely manner to alleviate the R\u0026D pipeline crisis. As a result, the transformation failed and faced a huge crisis.

Especially in the past ten years, Eisai has invested a huge amount of R\u0026D funds, but with little effect. Due to lack of innovation, the problem of patent cliff cannot be solved, and the company is currently in trouble.

And its biggest hit, donepezil, is an AD drug whose main effect is to improve the cognitive ability of Alzheimer's patients.

This undoubtedly hit the car hard with Sanqing's special AD medicine.

Almost in a blink of an eye, Eisai's blockbuster drug became uninterested, and sales plummeted.

This is no longer a problem of patent cliffs, but a complete dead end.

This medicine is completely useless.

This undoubtedly gave Eisai the final blow, and the company has since gone downhill.

As the CEO, Okada Murao has racked his brains for the past two years, relying on the domestic market to barely maintain his survival.

Although a lean camel is bigger than a horse, the company's revenue has dropped from the previous $6 billion to $2 billion.

Bad news is coming in one after another. Several new drug projects have been abandoned in a row. The money is spent, but there is no profit at all, and it is already beyond the means.

If no new performance point can be found, the company will become an ordinary generic pharmaceutical company sooner or later, thus embarking on the road of losing money and going bankrupt.

His face was yellow and haggard, and he looked at the work report in front of him with a frowning expression.

Looking at it, the veins on his forehead popped up, his eyes were red, and his eyes were full of anger, he said through gritted teeth.

"Damn Sanqing, it's their news again!"

"Ba Ge, it turned out to be the news of cooperation with major pharmaceutical companies, what a hell."

"It's all the fault of the Huaxia people who took away the market for Eisai's Alzheimer's disease drug and let us fall into this situation."

Mr. Okada gritted his teeth with hatred in his heart, but he had no choice but to slam the table in a helpless rage.

"I really hate it, why didn't Eisai develop these drugs, anti-cancer drugs, AD specific drugs, all should belong to the Yamato nation."

While cursing the Sanqing Group fiercely, he flipped through the work report.

Suddenly, he stopped, his eyes widened, staring at the paper in front of him.

After a long time, he gasped violently, his expression was filled with excitement, as if he had discovered something unbelievable.

"Fake, I didn't realize until today that this Wei Kang is good at improving discarded prescriptions."

"The Sanqing Group has been searching for all kinds of discarded prescriptions. It must have ulterior motives and other uses. It is impossible to really buy them back and have no use at all."

"Could it be that their medicines have been improved on the basis of discarded medicines, and then they have revived and succeeded?"

"In other words, in fact, many prescriptions have been successfully developed, but no one has discovered those new treatment directions."

"Ba Ge, why didn't I think of this."

"Maybe, we can also try to find a new treatment direction from the abandoned prescription?"

"This is undoubtedly much easier and less troublesome than developing innovative drugs from scratch."

"Is this the secret of Sanqing Group's success?"

"It's mine now!"